Pharma company hVivo reports 52% rise in revenues

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services

The Dublin-headquartered pharmaceutical services company said it expects to generate full year sales of £55m and earnings margins of 19 per cent Hvivo, the Irish pharmaceutical services company founded by businessman Cathal Friel, has increased its sales and

hVIVO, formerly Open Orphan, has today reported a jump in revenues and earnings for the six months to the end of June and said its outlook for the full year was “extremely positive”. It raised its 2023 revenue

Pharmaceutical clinical trial firm hVIVO has posted a 52% revenue growth and a doubling of its earnings as the company released its six month interim results. The group’s EBITDA margin also increased by 19%, as it took in earnings of

Dublin and London-listed pharmaceutical services company Hvivo delivered record revenues and grew its profit to almost £4 million (€4.6 million) in the first six months of this year, its interim results show. The company, formerly known as Open

hVIVO plc (HVO) on Tuesday raised its 2023 revenue forecast after the healthcare company reported a 52% jump in sales in the first half as demand for testing of infectious and respiratory disease therapies increased. Drugmakers are in a race

What does a day look like as a clinical trial volunteer? FluCamp is a leading clinical research organization focused on studying and developing treatments for respiratory illnesses. We conduct clinical trials and recruit volunteers to contribute to medical

The Dublin-headquartered pharmaceutical services company said the expanded facility would allow it to capitalise on its growing order book Hvivo, the Dublin-listed pharmaceutical services company founded by businessman Cathal Friel, has announced plans to move to a new,

The Irish-founded biotech Hvivo is expanding its operations in London to meet growing demand for its human challenge clinical trial services. Clinical-trial specialist biotech hVIVO has announced the planned expansion of its life sciences hub in Canary Wharf,

Pharmaceutical services firm Hvivo, formerly Open Orphan, has announced plans to open a larger facility in response to the company’s growing order book. Hvivo focuses on advancing research in infectious and respiratory diseases. The new facility will be

Hvivo, the pharmaceutical services company formerly known as Open Orphan, is to move to a new expanded facility in London on the back its “growing orderbook” and increased demand for its trial services. The company, which specialises in

An academic spin-off biotech with only a handful of people on board was preparing for their new biological entity for clinical development. For the drug product itself, they needed to a CMC process and conduct necessary nonclinical studies.

Speaker: Ion Tcacencu –  is an ATMP expert with over 17 years of experience as scientist within regenerative medicine and immunology, being responsible for projects developing new ATMPs. Ready to explore the cutting-edge world of Advanced Therapy Medicinal Products (ATMPs)? Don’t

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services

Dr. Andrew Catchpole, Chief Scientific Officer discusses hVIVO’s bespoke human challenge model development services focusing on our most recent Flu B model. He highlights the various stages of this contract & the fundamental steps hVIVO takes to ensure